11 Results for "

MDA 231

" in MedChemExpress (MCE) Product Catalog:
Products (11)

11 Results for "MDA 231" in MCE Product Catalog:

  • Targets Recommended:
5
5 Cited Publications
Cat. No.: HY-107999
CAS No.: 199735-88-1
Purity:  98.23%
Research Areas:  

Cancer

CADD522 is a RUNX2-DNA binding inhibitor (downregulates RUNX2-mediated transcription of downstream target genes), with an IC50 of 10 nM. CADD522 inhibits primary tumor growth and experimental metastasis of tumor cells in the lungs of immune-compromised mice. CADD522 can be used in study of cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-121983
CAS No.: 1130067-34-3
Purity:  98.95%
CAY10594 is an orally active PLD2 inhibitor with an IC50 of 140 nM. CAY10594 has activities such as anti-tumor, anti-oxidation and liver protection. CAY10594 can be used for the research of diseases like breast cancer, acute liver injury and colitis .
loading...
    loading...
Cat. No.: HY-N15759
CAS No.: 1214886-51-7
8,2'-Diprenylquercetin 3-methyl ether is isolated from Sinopodophyllum hexandrum (Royle) Ying (Sinopodophylli Fructus). 8,2'-Diprenylquercetin 3-methyl ether is cytotoxic to MDA-231 and T47D breast cancer cell lines .
loading...
    loading...
Cat. No.: HY-149407
Research Areas:  

Cancer

Multi-kinase-IN-4 (compound 5d) is multi-targeted kinase inhibitor, including VEGFR2, EGFR, HER2, and CDK2, with IC50 values of 0.33, 0.22, 0.18 and 2.09 μM, respectively. Multi-kinase-IN-4 shows broad-spectrum anti-cancer activities against HepG2, MCF-7, MDA-231, and HeLa cell lines (IC50 = 1.94–7.1 µM), but exhibits lower toxicity in the WI-38 cells (IC50 = 40.85 µM). Multi-kinase-IN-4 induces apoptosis and arrests cell cycle at S phase in HepG2 cells. Multi-kinase-IN-4 has the potential for the research of cancer .
loading...
    loading...
Cat. No.: HY-114503
CAS No.: 1099592-35-4
Purity:  98.45%
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

NSAH is a reversible and competitive nonnucleoside ribonucleotide reductase (RR) inhibitor, with cell-free IC50 of 32 μM and cell-based IC50 of ~250 nM, respectively .
loading...
    loading...
Cat. No.: HY-P990844

Target:  

Complement System

Anti-GC1q R/C1QBP Antibody (60.11) is a kind of mouse IgG1 κ chimeric antibody inhibitor, targeting to human GC1q R/C1QBP. Anti-GC1q R/C1QBP Antibody (60.11) can neutralize GC1q R. Anti-GC1q R/C1QBP Antibody (60.11) can be used for the researches of cancer, infection and inflammation, such as MDA231 tumor and S. aureus induced infective endocarditis (IE) .
loading...
    loading...
Cat. No.: HY-114503A
CAS No.: 54009-54-0
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

(E/Z)-NSAH is an isoform of NSAH (HY-114503), which is reversible and competitive nonnucleoside ribonucleotide reductase (RR) inhibitor, with cell-free IC50 of 32 μM and cell-based IC50 of ~250 nM, respectively .
loading...
    loading...
Cat. No.: HY-116543
CAS No.: 1323359-80-3
Target:  

Apoptosis

Research Areas:  

Cancer

ST362 is a anti-cancer agent. ST362 induces cell apoptosis and inhibits cancer cell growth .
loading...
    loading...
Cat. No.: HY-173365
Target:  

VEGFR

Research Areas:  

Cancer

VEGFR-2-IN-67 (Compound 6b) is an inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2). Its IC50 values for MDA-231 and MCF-7 cell lines are 5.91 µM and 7.16 µM respectively, and its inhibitory effect on VEGFR-2 is comparable to that of Sorafenib (HY-10201) (IC50 is 53.63 nM). VEGFR-2-IN-67 exerts significant anti-cancer activity through mechanisms such as inducing Apoptosis (the early apoptosis rate reaches 57.20%), arresting the cell cycle at the G1 phase, upregulating pro-apoptotic markers and downregulating Bcl-2. VEGFR-2-IN-67 can be used for research in the field of cancer .
loading...
    loading...
Cat. No.: HY-107999R
CAS No.: 199735-88-1
Research Areas:  

Cancer

CADD522 (Standard) is the analytical standard of CADD522 (HY-107999). This product is intended for research and analytical applications. CADD522 is a RUNX2-DNA binding inhibitor (downregulates RUNX2-mediated transcription of downstream target genes), with an IC50 of 10 nM. CADD522 inhibits primary tumor growth and experimental metastasis of tumor cells in the lungs of immune-compromised mice. CADD522 can be used in study of cancer .
loading...
    loading...
Cat. No.: HY-181099
Target:  

Apoptosis PI3K mTOR EGFR

Research Areas:  

Cancer

EGFR WT/T790M-IN-4 is an anticancer agent. EGFR WT/T790M-IN-4 acts as an inhibitor of EGFR WT and EGFR T790M , with an IC50 of 0.133 μM and 0.043 μM, respectively. EGFR WT/T790M-IN-4 also inhibits PI3K and mTOR kinases, with IC50 values of 0.22 μM and 0.35 μM, respectively. EGFR WT/T790M-IN-4 induces cell cycle arrest and apoptosis in cancer cells, and inhibits cancer cell proliferation. EGFR WT/T790M-IN-4 can be used in research related to prostate cancer, colon cancer and breast cancer .
loading...
    loading...
  • 1